GALIMEDIX THERAPEUTICS

galimedix-therapeutics-logo

Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments.

#Website #More

GALIMEDIX THERAPEUTICS

Industry:
Pharmaceutical Therapeutics

Address:
Kensington, Maryland, United States

Country:
United States

Website Url:
http://www.galimedix.com

Total Employee:
1+

Status:
Active

Contact:
972-4-9905139

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache


Official Site Inspections

http://www.galimedix.com

  • Host name: mi3-ts107.a2hosting.com
  • IP address: 66.198.240.20
  • Location: Ann Arbor United States
  • Latitude: 42.2503
  • Longitude: -83.8393
  • Metro Code: 505
  • Timezone: America/Detroit
  • Postal: 48106

Loading ...

More informations about "Galimedix Therapeutics"

Galimedix Therapeutics

At Galimedix, we are working to improve the lives of millions of patients worldwide by โ€ฆSee details»

About us โ€“ Galimedix Therapeutics

Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated โ€ฆSee details»

Galimedix Therapeutics - Crunchbase Company Profile & Funding

Galimedix Therapeutics is located in Kensington, Maryland, United States. Who invested in โ€ฆSee details»

Galimedix Therapeutics, Inc. | LinkedIn

Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to ...See details»

Galimedix Therapeutics GmbH - Innovations- und Gründerzentrum ...

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical โ€ฆSee details»

Partnering โ€“ Galimedix Therapeutics

Licensing agreement with TOI โ€“ an important first development and commercialization โ€ฆSee details»

Galimedix Therapeutics - PitchBook

Galimedix Therapeutics is headquartered in Kensington, MD. What is the size of Galimedix โ€ฆSee details»

Galimedix Therapeutics, Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Galimedix โ€ฆSee details»

Galimedix - Products, Competitors, Financials, Employees, โ€ฆ

Galimedix operates as an ophthalmic pharmaceutical company. It develops novel and โ€ฆSee details»

Galimedix Therapeutics - VentureRadar

Galimedix is a clinical stage pharmaceutical and ophthalmic company developing โ€ฆSee details»

Galimedix Therapeutics GmbH - Innovations- und โ€ฆ

Galimedix verfolgt das Ziel, neurodegenerative Prozesse an ihrem Ursprung zu stoppen und entwickelt bahnbrechende neuroprotektive Therapien zur Behandlung schwerer Augen- und Hirnerkrankungen, an denen Millionen โ€ฆSee details»

Galimedix Therapeutics, Inc. - GoingPublic.de

Galimedix is a Phase 2 clinical-stage private biotechnology company developing novel oral and โ€ฆSee details»

Théa and Galimedix enter into Licensing Agreement | Théa

Galimedix will grant TOI exclusive rights for the development and commercialization of GAL โ€ฆSee details»

Galimedix Therapeutics - Overview, News & Similar companies

Jun 15, 2021 Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing โ€ฆSee details»

Galimedix Therapeutics, Inc. | Insights

Apr 7, 2023 Galimedix; See more in Biomedtracker. Latest on Galimedix Therapeutics, Inc. โ€ฆSee details»

Our science โ€“ Galimedix Therapeutics

Galimedix is developing cutting-edge orally and topically administered Aฮฒ aggregation โ€ฆSee details»

BIO-Europe: Galimedix is developing amyloid beta aggregation โ€ฆ

Nov 5, 2024 BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try โ€ฆSee details»

News โ€“ Galimedix Therapeutics

Mar 8, 2024 Galimedix is proud to report that the inventor of the companyโ€™s groundbreaking โ€ฆSee details»

Galimedix Accelerating Development of Its Next-Generation Oral โ€ฆ

Jun 15, 2021 Galimedix's clinical R&D program is designed to leverage this sustained efficacy โ€ฆSee details»

Our Pipeline โ€“ Galimedix Therapeutics

Galimedix is developing amyloid beta (Aฮฒ) aggregation modulators as oral and topical drugs for โ€ฆSee details»